The interrelationship between diabetes mellitus and cardiovascular disease is well-documented, and, secondary to the latter, is the use of antiplatelet therapy. Although diabetes and the associated vascular manifestations are driving forces behind lower extremity amputations, few data are available on the risks of perioperative antiplatelet therapy with foot and ankle amputations. The goal of the present study was to address the surgical effect of continuing or discontinuing antiplatelet therapy before foot and/or ankle amputation. The following data were retrospectively collected: blood loss, pre- and postoperative hematocrit and hemoglobin, operative time, amputation type, age, diabetic status, antiplatelet treatment, and number of transfusions during the perioperative period. Perioperative antiplatelet therapy was defined as exposure to aspirin or clopidogrel within 3 days before surgery. To compare the outcomes between groups, the following factors were analyzed using bivariate analyses and then multivariate regression models: (1) the need for transfusions, (2) high blood loss (>20 mL), (3) volume of blood loss, and (4) operative time. The noninferiority of continued antiplatelet use was assessed in terms of operative time and blood loss, using a noninferiority margin of 10 minutes or 10 mL, respectively. Antiplatelet therapy was not a statistically significant risk factor for any of the studied outcomes on multivariate analysis. Equivalence testing revealed that continuing antiplatelet therapy is not inferior to discontinuing perioperative therapy in terms of blood loss and operative time. Multivariate analysis of the data suggested that antiplatelet therapy has no statistically significant impact on blood loss, transfusion rate, or operative time.
Level of Clinical Evidence
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The Journal of Foot and Ankle Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Peripheral arterial disease in diabetes—a review.Diabet Med. 2010; 27: 4-14
- Peripheral and cerebrovascular atherosclerotic disease in diabetes mellitus.Best Pract Res Clin Endocrinol Metab. 2009; 23: 335-345
- Amputations of the foot and ankle.in: Mann R.A. Coughlin M.J. Surgery of the Foot and Ankle. ed 6. Mosby, St. Louis1993: 1481-1507
- The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.Drugs. 2012; 72: 2087-2116
- Dual antiplatelet therapy with aspirin and clopidogrel: what is the risk in noncardiac surgery? A narrative review.Hosp Pract (1995). 2013; 41: 79-88
- The evolution of thienopyridine therapy clopidogrel duration, diabetes, and drug-eluting stents.J Am Coll Cardiol. 2008; 51: 2228-2229
- Benefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: from the NHLBI dynamic registry.Am J Cardiol. 2013; 111: 486-492
- ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery.J Am Coll Cardiol. 2007; 50: 1707-1732
- Antiplatelet therapy during perioperative period: double-edged sword.J Cardiol. 2014; 64: 331-333
- Aspirin, clopidogrel, and the surgeon.Adv Surg. 2014; 48: 211-222
- Clopidogrel is not associated with major bleeding complications during peripheral arterial surgery.J Vasc Surg. 2011; 54: 779-784
- Clopidogrel dilemma for orthopaedic surgeons.ANZ J Surg. 2011; 81: 774-784
- Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease.J Vasc Surg. 2015; 62: 157-165
- Does dual antiplatelet therapy affect blood loss and transfusion requirements in robotic-assisted coronary artery surgery?.Innovations (Phila). 2012; 7: 399-402
- Inter-society consensus for the management of peripheral arterial disease (TASC II).J Vasc Surg. 2007; 45: S5-S67
- Risk factors for coronary drug-eluting stent thrombosis: influence of procedural, patient, lesion, and stent related factors and dual antiplatelet therapy.ISRN Cardiol. 2013; 1: 1-8
- Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery: results of a multicentre registry.Thromb Haemost. 2015; 113: 272-282
- Safety of clopidogrel in hip fracture surgery.Mayo Clin Proc. 2013; 88: 149-156
- American Society of Anesthesiologists physical status classification.Indian J Anaesth. 2011; 55: 111-115
- ASA physical status classifications: a study of consistency of ratings.Anesthesiology. 1978; 49: 239-243
- The ASA classification of physical status—a recapitulation.Anesthesiology. 1978; 49: 233-236
- Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease.Diab Vasc Dis Res. 2010; 7: 274-288
- Antiplatelet therapy in populations at high risk of atherothrombosis.J Natl Med Assoc. 2006; 98: 711-721
- General thoracic surgery is safe in patients taking clopidogrel (Plavix).J Thorac Cardiovasc Surg. 2010; 140: 970-976
- Cardiovascular and bleeding risk of non-cardiac surgery in patients on antiplatelet therapy.J Cardiol. 2014; 64: 334-338
- Is discontinuation of clopidogrel necessary for intracapsular hip fracture surgery? Analysis of 102 hemiarthroplasties.J Orthop Traumatol. 2013; 14: 171-177
- Diabetic foot ulcerations: biomechanics, Charcot foot, and total contact cast.Semin Vasc Surg. 2012; 25: 66-69
- Diabetic vascular disease: characteristics of vascular disease unique to the diabetic patient.Semin Vasc Surg. 2012; 25: 89-92
- Lower extremity amputations—a review of global variability in Incidence.Diabetes Med. 2011; 28: 1144-1153
- Evolving techniques in foot and ankle amputation.J Am Acad Orthop Surg. 2010; 18: 223-235
- Estimating blood loss: can teaching significantly improve visual estimation?.Obstet Gynecol. 2004; 104: 601-606
- Estimation of blood loss during surgery.Ann R Coll Surg Engl. 1963; 33: 164-174
- Quantification of surgical blood loss.Vet Surg. 2006; 35: 388-393
Published online: September 07, 2016
Financial Disclosure: None reported.
Conflict of Interest: None reported.
© 2016 by the American College of Foot and Ankle Surgeons. All rights reserved.